Samuraciclib is primarily investigated for its potential in cancer treatment, particularly in targeting cyclin-dependent kinases (CDKs) which play a crucial role in cell cycle regulation. Its application is focused on inhibiting CDK7, a key enzyme involved in transcription and cell cycle progression, making it a promising candidate for treating various cancers, including breast cancer. By disrupting the activity of CDK7, samuraciclib aims to halt the proliferation of cancer cells and induce apoptosis, offering a targeted approach to therapy. It is currently undergoing clinical trials to evaluate its efficacy and safety in patients with advanced or metastatic cancers, especially those resistant to other treatments. The compound is also being explored in combination therapies to enhance its anticancer effects and improve patient outcomes.